HARMONi-GU1 Is First Global Registrational Clinical Trial of Ivonescimab in a Genitourinary (GU) Cancer, Adding to Global Phase III Ivonescimab Studies in NSCLC and CRC ...
NEW YORK , July 27, 2026 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Summit Therapeutics Inc. (NASDAQ: SMMT)...
Consistent Overall Survival Observed in Western, Asian Patients in Updated Analysis from Phase III HARMONi Study in EGFRm NSCLC Post-TKI Setting for Ivonescimab Plus Chemotherapy vs. Chemotherapy ...
Barchart Research What to Expect from SMMT Earnings SMMT Generated July 22, 2026 Current Price $14.74 EPS Estimate $$-0.26 Consensus Rating Moderate Buy Average Move 7.42% Summit Therapeutics: The Conference...
Data Expected to Be Generated by Mid-2027
Data Expected to Be Generated by Mid-2027
Western Patients Achieved OS HR of 0.76, Consistent with Asian Patients in this Global Phase III Study
Conference Call to Be Held at 4:30 p.m. EDT
Summit Therapeutics Inc. (NASDAQ: SMMT) today announced it has signed an agreement with Toronto-based Biossil, Inc. for the sale of ridinilazole, an investigational Phase III precision antibiotic owned...
The S&P 500 Index ($SPX ) (SPY ) on Wednesday closed down -1.62%, the Dow Jones Industrial Average ($DOWI ) (DIA ) closed down -1.87%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed down -1.98%. June...